drugset / Trial / NCT00458341

A Study of Ataluren in Pediatric Participants With Cystic Fibrosis

NCT00458341

Phase 2 Completed 30 enrolled PTC Therapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. Ataluren has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase functional CFTR protein in the cells of participants with CF due to a nonsense mutation.

Timeline

Start
2007-03-23
Primary completion
2008-02-29
Completion
2008-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ataluren Small molecule 4 mg/kg Oral
Subject Ataluren Small molecule 8 mg/kg Oral
Subject Ataluren Small molecule 10 mg/kg Oral
Subject Ataluren Small molecule 20 mg/kg Oral

Indications